In this episode, listen to Alice T. Shaw, MD, PhD, and Jessica J. Lin, MD, share their thoughts on the available and emerging clinical data for second-line and beyond treatments in patients with recurrent ROS1 -altered advanced NSCLC including: Assessing ROS1-TKI resistance mutations with tumor and liquid biopsies in patients with ROS1 -altered advanced NSCLC Previous TKI-treated cohort from the TRIDENT-1 study: efficacy of repotrectinib in patients with recurrent ROS1 -altered NSCLC and measurable baseline brain metastases Phase II TRUST-1 trial of taletrectinib: activity in patients with known ROS1 G2032R resistance mutation ROS1 -altered advanced NSCLC The global phase I/II ARROS-1 study of zidesamtinib (NVL-520): safety summary in patients with ROS1 -altered advanced NSCLC Program faculty: Jessica J. Lin, MD Attending Physician Massachusetts General Hospital Associate Professor of Medicine Harvard Medical School Boston, Massachusetts Alice T. Shaw, MD, PhD Chief, Strategic Partnerships Attending Physician, Thoracic Oncology Dana-Farber Cancer Institute Harvard Medical School Boston, Massachusetts Resources: To download the slides associated with this podcast discussion, please visit the program page . Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.
